EMCURE
Emcure Pharmaceuticals Limited (EMCURE) Stock Analysis
Emcure Pharmaceuticals Limited is an Indian pharmaceutical company developing and marketing formulations across therapeutic areas. It manufactures generics and specialty products for domestic and international markets. The company has R&D and manufacturing operations in India. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,833.50
-5.71% 1W | +34.80% 52W
Market Cap
34.8k CR
P/E Ratio
34.4
52W High
₹2100.7
52W Low
₹1306.5
Div. Yield
0.19%
Beta
-0.1
50 DMA
₹1931.3
200 DMA
₹1707.5
Profit Margin
10.4%
Inst. Own.
9.5%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,556 | 1,663 | 1,668 | 1,771 | 1,815 | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 |
| Expenses | 1,261 | 1,334 | 1,374 | 1,460 | 1,479 | 1,621 | 1,608 | 1,714 | 1,684 | 1,794 | 1,871 | 1,990 | 2,048 |
| Operating Profit | 296 | 329 | 294 | 311 | 336 | 381 | 355 | 402 | 417 | 475 | 493 | 480 | 532 |
| OPM % | 19% | 20% | 18% | 18% | 19% | 19% | 18% | 19% | 20% | 21% | 21% | 19% | 21% |
| Other Income | 15 | -2 | 22 | 12 | 23 | 36 | 4 | -6 | 0 | 3 | -36 | 14 | 2 |
| Interest | 52 | 59 | 61 | 65 | 59 | 46 | 32 | 39 | 27 | 33 | 38 | 46 | 32 |
| Depreciation | 67 | 70 | 84 | 91 | 94 | 97 | 97 | 97 | 99 | 105 | 105 | 106 | 110 |
| Profit before tax | 191 | 198 | 171 | 167 | 207 | 273 | 230 | 261 | 291 | 341 | 314 | 341 | 394 |
| Tax % | 26% | 26% | 30% | 27% | 26% | 26% | 32% | 24% | 26% | 26% | 26% | 29% | 26% |
| Net Profit | 141 | 146 | 120 | 121 | 153 | 202 | 156 | 197 | 215 | 251 | 231 | 244 | 292 |
| EPS in Rs | 7.21 | 7.69 | 6.27 | 6.36 | 7.95 | 10.29 | 8.11 | 9.97 | 10.92 | 12.84 | 12.16 | 12.84 | 15.50 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,717 | 5,049 | 5,033 | 5,855 | 5,986 | 6,658 | 7,896 | 9,204 | 9,683 |
| Expenses | 3,968 | 4,340 | 3,817 | 4,525 | 4,804 | 5,429 | 6,427 | 7,458 | 7,703 |
| Operating Profit | 749 | 708 | 1,216 | 1,330 | 1,182 | 1,230 | 1,469 | 1,746 | 1,980 |
| OPM % | 16% | 14% | 24% | 23% | 20% | 18% | 19% | 19% | 20% |
| Other Income | 72 | -25 | -159 | 63 | 39 | 47 | 62 | 100 | -17 |
| Interest | 223 | 257 | 155 | 176 | 214 | 237 | 176 | 144 | 148 |
| Depreciation | 267 | 321 | 250 | 245 | 260 | 312 | 384 | 415 | 425 |
| Profit before tax | 331 | 105 | 652 | 973 | 747 | 727 | 971 | 1,287 | 1,390 |
| Tax % | 37% | 4% | 36% | 28% | 25% | 27% | 27% | 27% | |
| Net Profit | 209 | 101 | 419 | 703 | 562 | 528 | 707 | 941 | 1,019 |
| EPS in Rs | 10.79 | 4.62 | 23.15 | 36.62 | 29.42 | 27.50 | 35.96 | 48.76 | 53.34 |
| Dividend Payout % | 32% | 54% | 4% | 8% | 7% | 7% | 8% | 7% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 15.0% | 13.0% | – |
| Profit CAGR | 21.0% | 18.0% | – |
Shareholding Pattern
Promoters77.92%
FIIs2.86%
DIIs2.84%
Public16.39%
Promoters77.88%
FIIs3.29%
DIIs4.36%
Public14.46%
Promoters77.87%
FIIs3.59%
DIIs6.10%
Public12.43%
Promoters77.87%
FIIs3.35%
DIIs6.10%
Public12.69%
Promoters77.83%
FIIs4.87%
DIIs8.46%
Public8.84%
Promoters77.92%
FIIs3.06%
DIIs3.44%
Public15.58%
Promoters77.87%
FIIs3.35%
DIIs6.10%
Public12.69%
Promoters77.83%
FIIs4.87%
DIIs8.46%
Public8.84%
EMCURE
Holdings Analysis
Key strengths & risk signals
81
Overall
84
Fundamental
79
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.19% yield - little to no income.
RECOVERY MODE! Current price (1833.5) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -5.7% (1 week), -4.2% (1 month), 1.1% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1931.3) is above 200-day average (1707.5) - positive signal.
GOOD YEAR! Stock gained 34.8% in the last year.
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 312,495 vs down days: 102,863. Ratio: 3.04x
Fundamental & Technical Analysis
81Overall
84Fundamental
79Technical
Fundamental Breakdown
Growth Quality
28/30
Revenue CAGR: 15.4% (VERY GOOD, 13/15). Profit CAGR: 20.2% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 10.4% profit margin - acceptable profitability.
PEG Valuation
8/10
FAIRLY VALUED! PEG of 1.70 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.19% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 15.05% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1931.3) is above 200-day average (1707.5) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (1833.5) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
GOOD YEAR! Stock gained 34.8% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 312,495 vs down days: 102,863. Ratio: 3.04x
RSI
4/5
APPROACHING OVERSOLD! RSI at 35.0 - watch for reversal.
52W Range
4/5
UPPER HALF! Trading at 66.4% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -5.7% (1 week), -4.2% (1 month), 1.1% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of -0.10 - stable stock, less market risk.
EMCURE
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-12 | Concall PDF | |
| Q4FY262026-05-11 | Concall PDF | |
| Q3FY262026-02-10 | Concall PDF | |
| Q2FY262025-11-17 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMCURE | ₹1,833.50 | 34.4 | 10.4% | 15.4% | 20.2% | +34.8% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
| WOCKPHARMA | ₹1,996.40 | 79.3 | 11.2% | 7.8% | – | +43.1% | 58 | CONSOLIDATION | -217.8% | -36.1% | +25.9% | -3.7% |
| AJANTPHARM | ₹3,410.10 | 37.6 | 19.6% | 13.4% | 21.6% | +41.1% | 76 | BREAKDOWN | +30.9% | +25.3% | +24.8% | +14.4% |
| NEULANDLAB | ₹20,890.00 | 53.8 | 21.0% | 18.5% | 30.6% | +28.8% | 73 | BREAKDOWN | +962.6% | -30.6% | +119.1% | -17.4% |
| PPLPHARMA | ₹196.90 | – | -3.4% | 7.6% | – | -2.6% | 57 | BOUNCE FROM SUPPORT | -15.1% | +688.6% | +17.4% | -17.5% |
| GRANULES | ₹815.20 | 30.3 | 11.8% | 5.9% | 4.8% | +48.7% | 64 | CONSOLIDATION | +59.9% | -10.7% | +21.2% | +0.5% |
| IPCALAB | ₹1,915.40 | 37.1 | 12.9% | 15.5% | 34.3% | +45.3% | 84 | BOUNCE FROM SUPPORT | +72.3% | +34.4% | +20.8% | +16.7% |
| GLAND | ₹3,061.80 | 44.7 | 16.8% | 21.3% | 9.6% | +63.8% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
Data from TradeAlone · Updated daily
EMCURE News
Emcure Pharmaceuticals Limited (emcure) Q1 FY27: Revenue Up 22.8%, PAT Surges 36.2%2026-08-06Emcure Pharmaceuticals Limited (emcure) to Expand the Use of Poviztra® for MASH Indication2026-07-20Emcure Pharmaceuticals Limited Consolidates Gennova Ownership; Sharpens Focus on Biologics2026-07-13Emcure Pharmaceuticals Limited (EMCURE) breaks out, gains 5% intraday2026-06-23Emcure Pharmaceuticals Limited (emcure) Announces Strong FY26 Results: Revenue Up 16.6%, Margin Expansion2026-06-12Emcure Pharmaceuticals Posts Strong Q4 FY26 Results With 16.6% Revenue Growth2026-05-05Emcure Pharmaceuticals Posts Strong Q4 FY26 Results With 16.7% Revenue Growth2026-05-05
